NDA 019216 · Abbvie
Fml Forte
Fluorometholone · Ophthalmic · Corticosteroid
Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Apr 23, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
31
5 Phase 3, 1 recruiting
FAERS reports
2,748
1,456 serious, 308 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 13, 2025.
INDICATIONS AND USAGE FML FORTE ® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 1986 Original approval · Type 3 - New Dosage Form
1 products under this application
- FML FORTE · FLUOROMETHOLONE 0.25% · SUSPENSION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluorometholone" as an intervention, any sponsor and status, largest first.
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) TrialPivotal-lookingCompleted
Massachusetts Eye and Ear InfirmaryAcademic, hospital or other
NCT04149210 · 2,410 participants · Start Aug 19, 2021 · Primary completion Nov 30, 2024
Drug: Fluorometholone 0.1% Oph Susp; Artificial Tears · For: Trachomatous Trichiasis (TT); Eye Diseases; Eyelid Diseases and 2 more
Sites: Addis Ababa, Ethiopia
- The OPTIMISE StudyPivotal-lookingRecruiting
Maastricht University Medical CenterAcademic, hospital or other
NCT05716945 · 342 participants (planned) · Start Jul 29, 2024 · Primary completion Sep 2028
Drug: Fluorometholone 0.1% Oph Susp; Dexamethasone 0.1% ophthalmic suspension · For: Pseudophakic Bullous Keratopathy; Fuchs' Endothelial Dystrophy; Intraocular Pressure
Sites: Apeldoorn, Netherlands; Nijmegen, Netherlands; Maastricht, Netherlands · 8 sites in all
- The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid RequirementsPivotal-lookingStatus unknown
United States Naval Medical Center, San DiegoFederal agency
NCT02030990 · 300 participants (planned) · Start Aug 2014 · Primary completion Jan 2023
Drug: Mitomycin-C; Fluorometholone 1% topical ocular steroid · For: Corneal Opacity
Sites: San Diego, California
- Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)Pivotal-lookingCompleted
Price Vision GroupIndustry
NCT01448213 · 264 participants · Start Oct 2011 · Primary completion Jan 2014
Drug: Prednisolone acetate; Fluorometholone · For: Fuchs' Dystrophy; Bullous Keratopathy
Sites: Indianapolis, Indiana; Erlangen, Germany
Benha UniversityAcademic, hospital or other
NCT05331859 · 250 participants (planned) · Start May 2022 · Primary completion Aug 2022
Drug: Insulin; autologous serum (AS) and 1 more · For: Corneal Epithelial Wound
Sites: Banhā, Egypt · 2 sites in all
- Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up StudyPivotal-lookingStatus unknown
Dr Salouti Eye Research CenterAcademic, hospital or other
NCT02974387 · 200 participants (planned) · Start Apr 2017 · Primary completion Aug 2017
Drug: Fluorometholone(FML); Loteprednol (Lotemax) · For: Must be PRK Candidate
- Fluorometholone StudyPivotal-lookingNot yet recruiting
Vishal JhanjiAcademic, hospital or other
NCT07308938 · 174 participants (planned) · Start Oct 31, 2026 · Primary completion Dec 31, 2029
Drug: Adjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy · For: Keratitis Bacterial; Corneal Ulcer (Diagnosis)
Sites: Pittsburgh, Pennsylvania
- Fluorometholone as Ancillary Therapy for TT SurgeryPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT01949454 · 154 participants · Start Nov 2013 · Primary completion Apr 2016
Drug: Fluorometholone 0.1% ophthalmic solution · For: Trichiasis; Trachoma; Bilamellar Tarsal Rotation
Sites: Butajīra, Ethiopia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure318
- fatigue201
- eye pain197
- drug ineffective192
- off label use187
- diarrhoea170
- headache168
- dyspnoea162
- arthralgia161
- condition aggravated146
- dizziness145
- pruritus139
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 5 |
| 2006 | 9 |
| 2007 | 9 |
| 2008 | 7 |
| 2009 | 15 |
| 2010 | 29 |
| 2011 | 28 |
| 2012 | 62 |
| 2013 | 46 |
| 2014 | 51 |
| 2015 | 68 |
| 2016 | 121 |
| 2017 | 125 |
| 2018 | 135 |
| 2019 | 147 |
| 2020 | 384 |
| 2021 | 173 |
| 2022 | 215 |
| 2023 | 229 |
| 2024 | 284 |
| 2025 | 330 |
| 2026 | 266 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fml Forte (Fluorometholone)
2024 spending
$898K
Beneficiaries
2,350
3,778 claims
Per beneficiary
$382
$33.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,563,978 |
| 2021 | $1,440,244 |
| 2022 | $796,841 |
| 2023 | $886,760 |
| 2024 | $897,562 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients.
Matsumura T, Iwasaki K, Arimura S, et al. · Sci Rep 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Topical Fluorometholone Versus Diclofenac Sodium in Cases With Perennial Allergic Conjunctivitis.
Li Z, Chen W, Zhang Y, et al. · Eye Contact Lens 2015 · Clinical Trial, Comparative Study
- Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial.
Shimazaki J, Tomida D, Yagi-Yaguchi Y, et al. · BMC Ophthalmol 2024 · Randomized Controlled Trial
- Fill levels, cost comparisons, and expulsion force requirements of commonly used topical ophthalmic steroids.
Gill MS, Murphy DA, Dvorak JD, et al. · J Cataract Refract Surg 2022 · Clinical Trial
- The effect of topical corticosteroids on laser-induced peripheral anterior synechiae.
West RH · Aust N Z J Ophthalmol 1992 · Clinical Trial, Comparative Study
- Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis.
Zhang X, Shen Z, Sun H, et al. · Int Ophthalmol 2023 · Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.